Research and Markets: Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/n59kb4/relapsed_chronic) has announced the addition of the "Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014" report to their offering.

This report provides comprehensive information on the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects.

This report features investigational drugs from across the globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team.

Drug profiles/records featured in the report undergo periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Relapsed Chronic Lymphocytic Leukemia (CLL)
  • The report reviews key pipeline products under drug profile section which includes product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Relapsed Chronic Lymphocytic Leukemia (CLL) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects

Companies Mentioned:

  • AbbVie
  • AstraZeneca
  • Boehringer Ingelheim
  • Celgene
  • Emergent BioSolutions
  • Genmab
  • GlaxoSmithKline
  • Infinity Pharmaceuticals
  • MorphoSys
  • Noxxon Pharma
  • Pharmacyclics
  • Portola Pharmaceuticals
  • SBI Biotech
  • Threshold Pharmaceuticals

For more information visit http://www.researchandmarkets.com/research/n59kb4/relapsed_chronic

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology

Sharing

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology